Bio News
$97 Million Series A Financing to Accelerate Development of Batten Disease and Huntington Disease Pipelines
Latus Bio has raised $97 million (approximately 140.6 billion won) to develop a gene therapy for Huntington disease. The funds will be used to develop the Batten disease treatment LTS-101, which is scheduled to enter clinical trials in the third quarter, and the Huntington disease treatment LTS-201. The company plans to submit an application to the U.S. Food and Drug Administration (FDA) to begin clinical trials of LTS-201 by the end of this year.
BIOBOOK TEAM
biobookmedia@biobook.co.krBrazilian Health Regulatory Agency Approves Gazyva for a New Indication in Systemic Lupus Erythematosus
Belgium’s Amadcell acquires two Lakefront CAR T therapies for up to $230 million
OrbiMed Raises $3 Billion, Its Largest Asia Fund to Date
UK Researchers Identify New Mechanism of Antifungal Drug Resistance in Candida auris
AstraZeneca Signs $1.5 Billion AI Drug Target Discovery Deal With Insitro
Hyundai Pharmaceutical’s Third-Quarter Operating Profit Reaches KRW 5.937 Billion, Up 44% Year Over Year
